AstraZeneca breached the terms of its Conditional Marketing Authorisation—time for lawyers to step in

I’ve known this from the beginning

The Conditional Marketing Authorisations (CMAs) for SARS-CoV-2 injections were in flagrant contravention of the rules governing the manufacture and distribution of medicinal products in the UK. These rules (legally enforceable by regulators) have been in place for over 40 years. As time has moved on, and various fatal, or near fatal ‘accidents’ have occurred due to bad practice in the pharmaceutical supply chain, they have been updated to make the rules more rigourous.

The reason I knew how bad these CMAs were from the beginning is that they dealt primarily with the clinical aspects, ignoring the vital role that the quality of the end-to-end supply chain plays in patient safety. That’s what you get in your arm—the stuff that’s manufactured and distributed by the supply chain—one mistake in there and patients can die, as evidenced below: